232 related articles for article (PubMed ID: 30535885)
41. Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases.
Blair HA; Deeks ED
BioDrugs; 2016 Oct; 30(5):469-480. PubMed ID: 27650650
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials.
Jørgensen KK; Goll GL; Sexton J; Bolstad N; Olsen IC; Asak Ø; Berset IP; Blomgren IM; Dvergsnes K; Florholmen J; Frigstad SO; Henriksen M; Hagfors J; Huppertz-Hauss G; Haavardsholm EA; Klaasen RA; Moum B; Noraberg G; Prestegård U; Rydning JH; Sagatun L; Seeberg KA; Torp R; Vold C; Warren DJ; Ystrøm CM; Lundin KEA; Kvien T; Jahnsen J
BioDrugs; 2020 Oct; 34(5):681-694. PubMed ID: 32965617
[TBL] [Abstract][Full Text] [Related]
43. Effectiveness and Safety of the Switch from Remicade® to CT-P13 in Patients with Inflammatory Bowel Disease.
Chaparro M; Garre A; Guerra Veloz MF; Vázquez Morón JM; De Castro ML; Leo E; Rodriguez E; Carbajo AY; Riestra S; Jiménez I; Calvet X; Bujanda L; Rivero M; Gomollón F; Benítez JM; Bermejo F; Alcaide N; Gutiérrez A; Mañosa M; Iborra M; Lorente R; Rojas-Feria M; Barreiro-de Acosta M; Kolle L; Van Domselaar M; Amo V; Argüelles F; Ramírez E; Morell A; Bernardo D; Gisbert JP
J Crohns Colitis; 2019 Oct; 13(11):1380-1386. PubMed ID: 30976785
[TBL] [Abstract][Full Text] [Related]
44. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.
Park W; Yoo DH; Jaworski J; Brzezicki J; Gnylorybov A; Kadinov V; Sariego IG; Abud-Mendoza C; Escalante WJ; Kang SW; Andersone D; Blanco F; Hong SS; Lee SH; Braun J
Arthritis Res Ther; 2016 Jan; 18():25. PubMed ID: 26795209
[TBL] [Abstract][Full Text] [Related]
45. Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies.
Takeuchi T; Nishikawa K; Yamada F; Morita A; Ohtsuki M; Suzuki Y; Watanabe M; Yamanaka H; Hibi T
Drug Saf; 2023 Oct; 46(10):991-1005. PubMed ID: 37700154
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.
Gecse KB; Lovász BD; Farkas K; Banai J; Bene L; Gasztonyi B; Golovics PA; Kristóf T; Lakatos L; Csontos ÁA; Juhász M; Nagy F; Palatka K; Papp M; Patai Á; Lakner L; Salamon Á; Szamosi T; Szepes Z; Tóth GT; Vincze Á; Szalay B; Molnár T; Lakatos PL
J Crohns Colitis; 2016 Feb; 10(2):133-40. PubMed ID: 26661272
[TBL] [Abstract][Full Text] [Related]
47. Safety and efficacy of switching from infliximab biosimilar CT-P13 to infliximab biosimilar SB2 in patients with inflammatory bowel disease.
Lovero R; Losurdo G; La Fortezza RF; Terracciano F; Biscaglia G; Martino G; Nardella M; Di Leo A; Principi M; Andriulli A; Bossa F
Eur J Gastroenterol Hepatol; 2021 Feb; 32(2):201-207. PubMed ID: 33369956
[TBL] [Abstract][Full Text] [Related]
48. Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease.
Bergqvist V; Kadivar M; Molin D; Angelison L; Hammarlund P; Olin M; Torp J; Grip O; Nilson S; Hertervig E; Lillienau J; Marsal J
Therap Adv Gastroenterol; 2018; 11():1756284818801244. PubMed ID: 30344642
[TBL] [Abstract][Full Text] [Related]
49. Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial.
Goll GL; Jørgensen KK; Sexton J; Olsen IC; Bolstad N; Haavardsholm EA; Lundin KEA; Tveit KS; Lorentzen M; Berset IP; Fevang BTS; Kalstad S; Ryggen K; Warren DJ; Klaasen RA; Asak Ø; Baigh S; Blomgren IM; Brenna Ø; Bruun TJ; Dvergsnes K; Frigstad SO; Hansen IM; Hatten ISH; Huppertz-Hauss G; Henriksen M; Hoie SS; Krogh J; Midtgard IP; Mielnik P; Moum B; Noraberg G; Poyan A; Prestegård U; Rashid HU; Strand EK; Skjetne K; Seeberg KA; Torp R; Ystrøm CM; Vold C; Zettel CC; Waksvik K; Gulbrandsen B; Hagfors J; Mørk C; Jahnsen J; Kvien TK
J Intern Med; 2019 Jun; 285(6):653-669. PubMed ID: 30762274
[TBL] [Abstract][Full Text] [Related]
50. Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study.
Trystram N; Abitbol V; Tannoury J; Lecomte M; Assaraf J; Malamut G; Gagnière C; Barré A; Sobhani I; Chaussade S; Amiot A
Aliment Pharmacol Ther; 2021 Apr; 53(8):887-899. PubMed ID: 33647174
[TBL] [Abstract][Full Text] [Related]
51. Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease.
Mahmmod S; Schultheiss JPD; van Bodegraven AA; Dijkstra G; Gilissen LPL; Hoentjen F; Lutgens MWMD; Mahmmod N; van der Meulen-de Jong AE; Smits LJT; Tan ACITL; Oldenburg B; Fidder HH
Inflamm Bowel Dis; 2021 Nov; 27(12):1954-1962. PubMed ID: 33538298
[TBL] [Abstract][Full Text] [Related]
52. Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease.
van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
Ther Drug Monit; 2019 Jun; 41(3):317-324. PubMed ID: 30633088
[TBL] [Abstract][Full Text] [Related]
53. Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients.
Pugliese D; Guidi L; Privitera G; Bertani L; Tolusso B; Papparella LG; Maltinti S; Di Mario C; Onali S; Ceccarelli L; Rapaccini GL; Scaldaferri F; Gremese E; Gasbarrini A; Costa F; Armuzzi A
Expert Opin Biol Ther; 2021 Jan; 21(1):97-104. PubMed ID: 33074723
[TBL] [Abstract][Full Text] [Related]
54. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry.
Glintborg B; Sørensen IJ; Loft AG; Lindegaard H; Linauskas A; Hendricks O; Hansen IMJ; Jensen DV; Manilo N; Espesen J; Klarlund M; Grydehøj J; Dieperink SS; Kristensen S; Olsen JS; Nordin H; Chrysidis S; Dalsgaard Pedersen D; Sørensen MV; Andersen LS; Grøn KL; Krogh NS; Pedersen L; Hetland ML;
Ann Rheum Dis; 2017 Aug; 76(8):1426-1431. PubMed ID: 28473425
[TBL] [Abstract][Full Text] [Related]
55. Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn's Disease Comparing, between CT-P13 and Originator Infliximab.
Park J; Cheon JH; Lee KM; Kim YH; Ye BD; Eun CS; Kim SH; Lee SH; Lee JH; Schreiber S
Gut Liver; 2023 May; 17(3):430-440. PubMed ID: 35975641
[TBL] [Abstract][Full Text] [Related]
56. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease.
Guerra Veloz MF; Argüelles-Arias F; Castro Laria L; Maldonado Pérez B; Benítez Roldan A; Perea Amarillo R; Merino Bohórquez V; Calleja MA; Caunedo Álvarez Á; Vilches Arenas Á
World J Gastroenterol; 2018 Dec; 24(46):5288-5296. PubMed ID: 30581277
[TBL] [Abstract][Full Text] [Related]
57. Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13.
Parigi TL; D'Amico F; Peyrin-Biroulet L; Danese S
Expert Opin Biol Ther; 2021 Jan; 21(1):37-46. PubMed ID: 32799561
[TBL] [Abstract][Full Text] [Related]
58. Short article: Remicade infusions at home: an alternative setting of infliximab therapy for patients with Crohn's disease.
Kuin S; Stolte SB; van den Brink GR; Ponsioen CY; Fockens P; D'Haens GR; Löwenberg M
Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):222-5. PubMed ID: 26566062
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.
Yoo DH; Prodanovic N; Jaworski J; Miranda P; Ramiterre E; Lanzon A; Baranauskaite A; Wiland P; Abud-Mendoza C; Oparanov B; Smiyan S; Kim H; Lee SJ; Kim S; Park W
Ann Rheum Dis; 2017 Feb; 76(2):355-363. PubMed ID: 27130908
[TBL] [Abstract][Full Text] [Related]
60. The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13.
Reinisch W; Louis E; Danese S
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():17-26. PubMed ID: 26395531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
